Immatics N.V Stock Price, News & Analysis

Immatics (NASDAQ: IMTX) reported Q1 2025 financial results and provided updates on its PRAME-targeted cancer immunotherapy programs. The company's lead candidate, IMA203 PRAME cell therapy, is advancing in the Phase 3 SUPRAME trial for melanoma, with enrollment expected to complete in 2026. Immatics maintains a strong financial position with $588.1 million in cash and equivalents, providing runway into 2H 2027. Key developments include FDA IND clearance for a combination trial with Moderna's PRAME therapy and ongoing trials for multiple product candidates. The company reported a net loss of $43.2 million for Q1 2025, compared to $2.4 million in Q1 2024, primarily due to lower revenue and forex losses. R&D expenses increased to $45.3 million from $34.7 million year-over-year, reflecting advancement in clinical trials. The company will present updated IMA203 melanoma data at the 2025 ASCO Annual Meeting.

Immatics (NASDAQ: IMTX) has announced upcoming presentations of its IMA203 TCR T-cell therapy at the 2025 ASCO Annual Meeting in Chicago. The presentations will feature:

1. An oral presentation with updated data from the Phase 1b trial of IMA203 in metastatic melanoma patients, including extended follow-up data since October 2024 and additional uveal melanoma patient data.

2. A trial-in-progress poster presentation on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior checkpoint inhibitor treatment.

The full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET. The presentations are scheduled for May 31 and June 2, 2025, during the Developmental Therapeutics - Immunotherapy sessions.

Immatics (NASDAQ: IMTX) reported its full year 2024 financial results and business updates. The company's lead TCR-T cell therapy, IMA203, targeting PRAME in advanced melanoma, has entered Phase 3 trial (SUPRAME) with first patient randomized. Key highlights include:

Phase 1b IMA203 data showed 54% confirmed response rate, 12.1 months median duration of response, and 6 months median progression-free survival in advanced melanoma patients. The company's cash position stands at $628.0 million, extending runway into second half of 2027.

Notable developments include:

• SUPRAME Phase 3 trial enrollment continuing as planned, targeting 360 patients
• Manufacturing facility ready for commercial production with >95% success rate
• IMA203CD8 (second-generation therapy) showing 41% confirmed response rate
• TCER® IMA402 and IMA401 programs advancing with promising initial clinical data

Immatics reported Q3 2024 financial results and clinical updates for its cancer immunotherapy pipeline. Key highlights include first clinical data from TCER® IMA402 showing favorable tolerability and initial responses in melanoma patients. The company plans to start SUPRAME, a Phase 3 trial for ACTengine® IMA203 in melanoma patients, in December 2024. Financial position remains strong with $549.2 million in cash and equivalents as of September 30, 2024, plus an additional $150 million from October's public offering, extending cash runway into 2H 2027. Q3 revenue was $56.7 million, with a net loss of $9.6 million.

Immatics (NASDAQ: IMTX) announced clinical data updates for its TCR-T therapy candidates targeting PRAME. The ACTengine® IMA203 demonstrated 54% confirmed objective response rate (cORR) and 12.1 months median duration of response in metastatic melanoma patients. The company plans to initiate SUPRAME, a Phase 3 trial, in December 2024. The next-generation IMA203CD8 showed enhanced pharmacology and potency, with the Phase 1a dose escalation study being reinitiated to target higher doses for solid cancers with medium-level PRAME copy numbers. The company expects to report initial clinical data from the TCER® IMA402 Phase 1a trial by year-end.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced the pricing of its public offering. The company is offering 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and offering expenses.

The offering is set to close on October 15, 2024, subject to customary closing conditions. Immatics has also granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount. Jefferies, BofA Securities, and Leerink Partners are acting as joint book-running managers for the offering.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced the commencement of an underwritten public offering of its ordinary shares. The offering, subject to market conditions, has no guaranteed completion or defined terms. Jefferies, BofA Securities, and Leerink Partners are acting as joint book-running managers. A registration statement has been filed with the SEC and became effective on October 10, 2024. The offering will be made through a prospectus supplement and accompanying prospectus, available on the SEC's website. This announcement does not constitute an offer to sell or a solicitation of an offer to buy these securities.

Immatics announced updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in 28 heavily pretreated metastatic melanoma patients. Key findings include:

- Confirmed objective response rate of 54% with median duration of response of 12.1 months
- Median progression-free survival (PFS) of 6 months
- Favorable tolerability profile maintained
- Patients with deep responses show median PFS of more than one year

Based on these results, Immatics will proceed to a registration-enabling Phase 3 trial called 'SUPRAME'. This trial will enroll 360 patients with unresectable or metastatic melanoma post-treatment with a checkpoint inhibitor. The primary endpoint for full approval will be median PFS. The trial is set to commence in December 2024, with enrollment forecasted to complete in 2026.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced upcoming presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6-10, 2024. The company will deliver two oral presentations and five poster presentations.

The oral presentations will cover:

• ACTengine IMA203 TCR-T targeting PRAME, showing deep and durable anti-tumor activity in heavily pretreated solid cancer patients
• Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME

The poster presentations will address various topics including T cell persistence monitoring, allogeneic γδ T cell production, PRAME-targeting therapies, and TCR-engineered T cells with enhanced persistence.